Syntara Ltd Asset Resilience Ratio

Latest as of June 2005: 85.55%

Syntara Ltd asset resilience ratio. Syntara Ltd (SNT) has an Asset Resilience Ratio of 85.55% as of June 2005. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Syntara Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

AU$32.45 Million
≈ $22.96 Million USD Cash + Short-term Investments

Total Assets

AU$37.94 Million
≈ $26.84 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of Syntara Ltd (2005–2023)

Asset resilience ratio of Syntara Ltd from 2005 to 2023. This chart shows how Syntara Ltd's Asset Resilience Ratio has changed over time. Read debt load of Syntara Ltd for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Syntara Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Syntara Ltd assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$32.45 Million 85.55%
Total Liquid Assets AU$32.45 Million 85.55%

Asset Resilience Insights

  • Very High Liquidity: Syntara Ltd maintains exceptional liquid asset reserves at 85.55% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Syntara Ltd Industry Peers by Asset Resilience Ratio

Compare Syntara Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Ajanta Pharma Limited
NSE:AJANTPHARM
Drug Manufacturers - Specialty & Generic 14.99%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 5.50%
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
Drug Manufacturers - Specialty & Generic 26.45%
Porton Fine Chemicals Ltd
SHE:300363
Drug Manufacturers - Specialty & Generic 6.85%
Jubilant Pharmova Limited
NSE:JUBLPHARMA
Drug Manufacturers - Specialty & Generic 1.26%

Syntara Ltd Asset Resilience Ratio by Year (2005–2023)

Syntara Ltd asset resilience ratio by year from 2005 to 2023. The table below shows the annual Asset Resilience Ratio data for Syntara Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-06-30 36.40% AU$8.75 Million
≈ $6.19 Million
AU$24.03 Million
≈ $17.00 Million
+2.67pp
2022-06-30 33.73% AU$8.49 Million
≈ $6.01 Million
AU$25.19 Million
≈ $17.82 Million
-51.82pp
2005-06-30 85.55% AU$32.45 Million
≈ $22.96 Million
AU$37.94 Million
≈ $26.84 Million
--
pp = percentage points

About Syntara Ltd

AU:SNT Australia Drug Manufacturers - Specialty & Generic
Market Cap
$20.80 Million
AU$29.39 Million AUD
Market Cap Rank
#24788 Global
#1009 in Australia
Share Price
AU$0.02
Change (1 day)
+0.00%
52-Week Range
AU$0.02 - AU$0.04
All Time High
AU$0.40
About

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more